Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

Published:2010-08-17 Issue:6 Volume:103 Page:837-844
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Santoro A,Pressiani T,Citterio G,Rossoni G,Donadoni G,Pozzi F,Rimassa L,Personeni N,Bozzarelli S,Rossoni G,Colombi S,De Braud F G,Caligaris-Cappio F,Lambiase A,Bordignon C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605858.pdf

Reference27 articles.

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor J, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293

2. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377–380

3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci 72: 3666–3670

4. Cheng AL, Kang YK, Chen Z, et Tsao CJ, Qin S, Kim JS, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WJ, Pan H, Burok K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25–34

5. Corti A, Ponzoni M (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 1028: 104–112

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α;Pharmaceutics;2022-07-06

2. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study;The Oncologist;2020-10-31

3. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target;Journal of Oncology;2020-02-24

4. Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy;Molecular Imaging;2020-01-01

5. The mercapturic acid pathway;Critical Reviews in Toxicology;2019-11-26